

Table 14-3.06
CIBIC+ - Summary at Week 16 - LOCF

| | Placebo (N=79) | Xanomeline Low Dose (N=81) | Xanomeline High Dose (N=74) |
|------------------------------------|-------------------|----------------------------------|-----------------------------------|
| Week 16 | | | |
| n | 79 | 81 | 74 |
| Mean (SD) | 4.2 (0.70) | 4.0 (0.77) | 4.0 (0.75) |
| Median (Range) | 4.0 (3;6) | 4.0 (2;6) | 4.0 (2;5) |
| p-value(Dose Response) [1][2] | | | 0.214 |
| p-value(Xan - Placebo) [1][3] | | 0.219 | 0.272 |
| Diff of LS Means (SE) | | -0.1 (0.12) | -0.1 (0.12) |
| 95% CI | | (-0.4;0.1) | (-0.4;0.1) |
| p-value(Xan High - Xan Low) [1][3] | | | 0.916 |
| Diff of LS Means (SE) | | | 0.0 (0.12) |
| 95% CI | | | (-0.2;0.2) |

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors.

[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.

[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.